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Phosphatases are recognized to have important functions in the initiation of skeletal mineralization.
Tissue-nonspeciﬁc alkaline phosphatase (TNAP) and PHOSPHO1 are indispensable for bone and cartilage
mineralization but their functional relationship in the mineralization process remains unclear. In this
study, we have used osteoblast and ex-vivo metatarsal cultures to obtain biochemical evidence for co-
operativity and cross-talk between PHOSPHO1 and TNAP in the initiation of mineralization. Clones 14
and 24 of the MC3T3-E1 cell line were used in the initial studies. Clone 14 cells expressed high levels of
PHOSPHO1 and low levels of TNAP and in the presence of β-glycerol phosphate (βGP) or phosphocholine
(P-Cho) as substrates and they mineralized their matrix strongly. In contrast clone 24 cells expressed
high levels of TNAP and low levels of PHOSPHO1 and mineralized their matrix poorly. Lentiviral Phospho1
overexpression in clone 24 cells resulted in higher PHOSPHO1 and TNAP protein expression and in-
creased levels of matrix mineralization. To uncouple the roles of PHOSPHO1 and TNAP in promoting
matrix mineralization we used PHOSPHO1 (MLS-0263839) and TNAP (MLS-0038949) speciﬁc inhibitors,
which individually reduced mineralization levels of Phospho1 overexpressing C24 cells, whereas the si-
multaneous addition of both inhibitors essentially abolished matrix mineralization (85%; Po0.001).
Using metatarsals from E15 mice as a physiological ex vivomodel of mineralization, the response to both
TNAP and PHOSPHO1 inhibitors appeared to be substrate dependent. Nevertheless, in the presence of
βGP, mineralization was reduced by the TNAP inhibitor alone and almost completely eliminated by the
co-incubation of both inhibitors. These data suggest critical non-redundant roles for PHOSPHO1 and
TNAP during the initiation of osteoblast and chondrocyte mineralization.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tissue-nonspeciﬁc alkaline phosphatase (TNAP) is the isozyme
of the alkaline phosphatase family whose activity is linked to the
promotion of matrix mineralization in bone and cartilage [1]. In-
deed, both a Pi-generating function, as well as the ability to hy-
drolyze a mineralization inhibitor were proposed for TNAP since
the discovery of this enzyme in bone [2]. A primary inhibitor of
ECM mineralization is extracellular inorganic pyrophosphate (PPi)B.V. This is an open access article u
esa),[3], produced ectoplasmically by the enzymatic action of nucleo-
tide pyrophosphatase/phosphodiesterase-1 (NPP1) on extra-
cellular ATP [4]. Intracellularly produced PPi is also transported to
the extracellular milieu by the channeling function of the anky-
losis protein (ANK) [5]. TNAP activity is crucial for restricting the
concentration of extracellular PPi to maintain a Pi/PPi ratio per-
missive for normal bone mineralization [6,7]. Indeed, lack of TNAP
function (Alpl /) leads to the soft bones condition known as
hypophosphatasia (HPP), caused by accumulation of extracellular
PPi that blocks the propagation of HA onto the ECM [8,9]. How-
ever, chondrocyte- and osteoblast-derived matrix vesicles (MV)
derived from both HPP patients and Alpl / mice retain the ability
to initiate intravesicular mineral formation and contain HA crystals
[10,11] demonstrating that TNAP is not essential for the initiation
of MV mediated ECM mineralization.
Instead, PHOSPHO1, a member of the haloacid dehalogenase
superfamily [12,13] highly expressed in mineralizing cartilage,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MV-mediated mineralization. PHOSPHO1 shows high phospho-
hydrolase activity towards phosphoethanolamine (P-Etn) and
phosphocholine (P-Cho) and is active inside chondrocyte- and
osteoblast derived MVs where it may have a role scavenging Pi
from MV membrane phospholipids to favor intra-vesicular HA
deposition [17,18]. Small molecule compounds that inhibit
PHOSPHO1 activity in Alpl / MVs cause a signiﬁcant decrease in
MV-mediated calciﬁcation in vitro [15] and the absence of PHOS-
PHO1 results in a lower accumulation of mineral, which leads to a
more deformable bone [19]. Therefore, Phospho1 / mice show
skeletal abnormalities that include decreased bone mineral den-
sity, spontaneous fractures, osteomalacia and scoliosis. However,
lack of PHOSPHO1 does not prevent the intravesicular deposition
of mineral, although the double ablation of Phospho1 and Alpl lead
to complete lack of skeletal mineralization [20]. Here, we have
used osteoblast and ex-vivo metatarsal cultures to obtain bio-
chemical evidence for co-operativity and cross-talk between
PHOSPHO1 and TNAP in the initiation of mineralization.2. Methods
2.1. Animals
Phospho1‐R74X null mutant (Phospho1 /) mice were gener-
ated by N‐ethyl‐N‐nitrosourea mutagenesis in a C3HeB/FeJ (Stock
No. 000658, Jackson Laboratories, Bar Harbor, ME, USA) back-
ground, then bred to C57BL/6 mice to segregate other possible
undesired mutations [20]. All animal experiments were approved
by Roslin Institute's Animal Users Committee, and the animals
were maintained in accordance with Home Ofﬁce (UK) guidelines
for the care and use of laboratory animals.
2.2. Cell culture
Previously characterized clones 14 and 24 of the MC3T3-E1 cell
line ([21]; a generous gift of Prof Renny Franceschi, Michigan, USA)
were cultured in maintenance medium (α-MEM (Invitrogen,
Paisley, UK) containing 10% (v/v) fetal bovine serum (FBS, (In-
vitrogen) and 0.05 mg/ml gentamycin (Invitrogen)) at 37° C in 5%
CO2.
2.3. Lentiviral vectors and cell infection
Mouse Phospho1 sequence was ampliﬁed from mouse primary
osteoblast cDNA adding a FLAG tag sequence to the 5′ end and
cloned into a commercially available pLVX vector (Clonetech
Mountain View, CA, USA). An empty vector was used as control.
For Lentivirus packaging, a T25 tissue culture ﬂask was seeded
with 1.6106 HEK293T cells in 6mls medium (DMEM, 10% FBS, 1%
NEAA; Invitrogen), incubated for 24 h and transfected when 70–
90% conﬂuent. The transfection mix was set up in 145 μl Opti-
Mem (Invitrogen) containing 2 μg psPAX2, 1 μg of VSV-G and
1.5 μg of the desired pLVX plasmid and 17 μl of Fugene HD (Roche,
East Sussex, UK). The transfection mix was incubated for 15 min at
room temperature prior to adding to the cells. The transfected cells
were incubated at 37 °C in 5% CO2 overnight and the medium was
collected 24 and 48 h post transfection to concentrate and titrate
the virus. MC3T3-E1 clones were plated at 2105 cells per T25
ﬂask and transduced the next day with the desired lentivirus at
2 virus particles per cell plated. Selection was done by antibiotic
selection with puromycin (Invitrogen) at a ﬁnal concentration
2 mg/ml.2.4. Expression and preparation of test enzymes
Recombinant human PHOSPHO1 and TNAP protein was pro-
duced and puriﬁed as previously described [17]. Enzyme reactions
were initiated by the addition of P-Cho and allowed to proceed for
60 min at room temperature and pH 7.3 as previously described
[22].
2.5. Mineralization cultures
Cells were plated at 2.5104 cells per well in 12 well plates
and cultured in maintenance medium for two days before chan-
ging to mineralization medium (maintenance mediumþ50 mg/ml
ascorbic acid and 5 mM β-glycerol phosphate (βGP; Sigma) or
3 mM P-Cho (Sigma) as phosphate donors. PHOSPHO1 and TNAP
inhibitors, MLS-0263839 and MLS-0038949 (both 30 mM) were
added where indicated. This concentration was derived from our
previous dose response experiments and showed maximum en-
zyme inhibition and no cellular toxicity [22]. Mediumwas changed
every 3–4 days for up to 21 days. Cells were ﬁxed for alizarin red
staining or lysed for protein or mRNA extraction.
2.6. Alizarin red staining for matrix mineralization
Cells were ﬁxed with 4% paraformaldehyde for 30 min at RT,
prior to staining with 2% alizarin red, pH 4.2. After image capture,
the cells were destained with 10% cetylpyridium chloride and the
optical density determined at 570 nm [23].
2.7. Western Blotting
Cells were lysed in RIPA buffer (20 mM Tris–HCl, pH. 8.0,
135 mM NaCL, 10% glycerol, 1% IGEPAL, 0.1% SDS, 0.5% Na deox-
ycholate, 2 mM EDTA; Invitrogen) containing “complete” protease
inhibitor cocktail according to manufacturer's instructions (Roche)
and protein concentration determined using the standard DC assay
(Bio-Rad, Hemel Hempsted, UK). Proteins (8 mg) were run in a 10%
Bis-Tris gel (Invitrogen) and transferred to a nitrocellulose mem-
brane. The membrane was blocked with Odyssey blocking buffer
(LI-COR Biosciences, Nebraska, USA) for 1 h and probed overnight
at 4 °C with anti-PHOSPHO1 (recombinant Fab, AbD Serotec,
Martinsried/Planegg, Germany) anti-TNAP (R&D, Abingdon, UK)
and anti ß-actin (Cell signaling technology, Hitchin, UK) antibodies
diluted 1:1000,1:500 and 1:1000 respectively in Odyssey blocking
buffer. After washing in PBS the membranes were incubated with
goat anti-Human (800CW), goat anti-Rat (800CW) and goat anti-
Rabbit (680 RD) for 50 min (LI-COR Biosciences, 1:1250 dilution in
Odyssey blocking buffer). The resulting blots were subsequently
washed in PBS and visualized using the LI-COR Odyssey infrared
scanner and software (LI-COR biosciences) with a scan resolution
of 169 mm.
2.8. Analysis of gene expression using quantitative RT-PCR
RNA was extracted from cells using RNeasy total RNA (Qiagen
Ltd., Crawley, UK), according to the manufacturer's instructions.
For each sample, total RNA content was assessed by absorbance at
260 nm and purity by A260/A280 ratios by NanoDrop (Fischer
Scientiﬁc, Loughborough, UK). RNA was reverse transcribed and
the PCR reaction undertaken as described previously [24]. All
genes were analyzed with the SYBR green detection method using
the Stratagene Mx3000P real-time QPCR system (Stratagene, CA,
USA). Each sample was assayed in triplicate. All gene expression
data were normalized against the house keeping gene, Atp5b
(Primer Design, Southampton, UK). The control values are ex-
pressed as 1 to indicate a precise fold change value for each gene
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CAACA, Reverse; TGAGGATGCGGCGGAATAA) and Alpl (Forward 5′
GGG ACG AAT CTC AGG GTA CA3′, Reverse 5′AGT AAC TGG GGT
CTC TCT CTT T3′). Data were analysed by the delta delta Ct method.
2.9. Metatarsal culture
Embryonic metatarsal organ cultures provide a well-estab-
lished ex vivo model of endochondral bone growth [25,26]. In
addition, 15-day-old fetal metatarsal bones (E15) are comprised of
early proliferating chondrocytes with no evidence of a mineralized
core and are therefore an informative physiological model to in-
vestigate the effects of TNAP and PHOSPHO1 on the initiation of
bone mineralization [23,27]. Metatarsals from E15 WT and
Phospho1 / mice were cultured as previously described [23] and
PHOSPHO1 (30 mM) and TNAP (30 mM) inhibitors were added
where indicated. Metatarsals were maintained in medium for at
least 7 days (no medium change) and the length of the miner-
alization zone and of the whole bone was measured as previously
described [23]. Bone mineralization status of each culture was
assessed by calculating the ratio of the length of the mineralized
zone over the total length of the bone.
2.10. Statistics
SigmaStat v 11.0 was used for statistical analysis. Data
(mean7SEM) comparison was conducted by regular t-tests or
ANOVA unless the data was not normally distributed, in which
case a suitable non-parametric test was selected.0.0
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Fig. 2. TNAP and PHOSPHO1 expression in MC3T3 clones 14 and 24. MC3T3s were
cultured in the presence of 50 mg/ml Ascorbic Acid (AA) with 5 mM βGP or 3 mM
P-Cho as substrates and analysed for (A) TNAP and PHOSHO1 protein expression (B)
Alpl gene expression and (C) and Phospho1 gene expression. n¼3. ***Po0.001.3. Results
3.1. Effect of substrate choice on in vitro osteoblast ECM
mineralization
Although βGP can be hydrolyzed by PHOSPHO1 to release Pi it
has been previously reported to be a poor substrate for PHOSPHO1
in comparison to TNAP [17,22]. We therefore ﬁrst determined the
potential of P-Cho and βGP as phosphate donors for ECM miner-
alization of MC3T3-E1 clones 14 and 24. These clones were chosen
because of their reported differences in TNAP expression and mi-
neralization ability [21]. The supplementation of clone 14 cultures
by βGP or P-Cho promoted mineralization from day 7 onwards
(Fig. 1A and B). It is possible that during the process of miner-
alization and the destruction of MVs, PHOSPHO1 is released into
the extracellular milieu and is able to generate Pi from the added
substrates. NPP1 can also act as an efﬁcient phosphatase in the
absence of TNAP and this may be another potential source of Pi for
mineral formation [28]. Matrix mineralization of clone 24 cells inFig. 1. In vitro substrate mineralization assay on MC3T3 clones 14 and 24. MC3T3s were
P-Cho as substrates and (A) stained with alizarin red and (B) quantiﬁed after leaching.the presence of βGP also was noted from day 7 onwards but, as
expected, was less than their clone 14 counterparts. Mineralization
in the presence of P-Cho was also less and its initiation was de-
layed till day 14 of culture (Fig. 1A and B). Whilst clone 24 mi-
neralizes its matrix poorly it had greater TNAP expression than the
more highly mineralizing clone 14 (Fig. 2A and B). In contrast,
PHOSPHO1 expression by clone 14 was higher than that of clone
24 at both the gene and protein level (Fig. 2A and C). These data0
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Fig. 3. Overexpression of Phospho1 in MC3T3 clone 24 cells. (A) Phospho1 expression levels in cells transfected with empty vector (black bars) or Phospho1 overexpression
vector (gray bars). (B) Mineralization after 14 days in cells transfected with empty vector (EV) or Phospho1 overexpression vector (OE) and cultured with 50 mg/ml of AA and
5 mM βGP or 3 mM P-Cho. (C) Western blotting of TNAP and PHOSPHO1 protein expression in EV or OE cells cultured with 50 mg/ml of AA and 5 mM βGP or 3 mM P-Cho.
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PHOSPHO1 (Supplemental Fig. 1), was a suitable phosphate sub-
strate for the promotion of ECM mineralization and that poor ECM
mineralization of MC3T3-E1 clone 24 cells was associated with
very low PHOSPHO1 expression.
3.2. Phospho1 overexpression induces ECM mineralization
To directly assess the co-operativity and cross-talk between
PHOSPHO1 and TNAP expression in ECM mineralization we over-
expressed Phospho1 in clone 24 cells which had low Phospho1
expression and mineralized their ECM poorly. This resulted in an
8-fold increase in Phospho1 expression in cells maintained under
non-mineralizing conditions (Fig. 3A). When cultured in the pre-
sence of βGP or P-Cho, Phospho1 overexpression resulted in higher
PHOSPHO1 and TNAP protein expression and increased levels of
matrix mineralization (Fig. 3B and C). The increased TNAP ex-
pression by βGP (Fig. 3C) has been noted previously [29]. Despite
increased TNAP expression it was, in the absence of higherFig. 4. Inhibition of osteoblast and metatarsal matrix mineralization. (A) Clone 14 cells a
TNAP inhibitors alone and in combination. n¼4. * Po0.05, ***Po0.001.PHOSPHO1 expression, unable to promote matrix mineralization
possibly implicating the necessity for PHOSPHO1 in mineral
initiation.3.3. Joint PHOSPHO1 and TNAP activity is required for MC3T3 matrix
mineralization
TNAP (MLS-0038949) and PHOSPHO1 (MLS-0263839) in-
hibitors were tested on Phospho1 overexpressing clone 24 cells in
the presence of 3 mM P-Cho to avoid interference from βGP in-
duced TNAP expression (Fig. 3C). At 30 mM no cell toxicity was
observed and this is in agreement with our previous reports [22].
Phospho1 overexpression induced a 2.8 fold increase (Po0.01) in
alizarin red staining, which was reduced (72%; Po0.01) to control
(empty vector transduced) levels after treatment with MLS-
0263839. The PHOSPHO1 inhibitor did not however alter ECM
mineralization of control cells possibly reﬂecting their low level of
endogenous PHOSPHO1 expression (Fig. 4A). The TNAP inhibitor
also reduced matrix mineralization of both control (75%; Po0.05)nd (B) metatarsals show reduced mineralization in the presence of PHOSPHO1 and
C. Huesa et al. / Biochemistry and Biophysics Reports 4 (2015) 196–201200and Phospho1 overexpressing (63%; Po0.01) cells, possibly re-
ﬂecting the inhibition of both basal (control) and Phospho1-in-
duced TNAP activity. The simultaneous addition of both inhibitors
essentially abolished ECM mineralization in Phospho1 over-
expressing cells (85%; Po0.001) (Fig. 4A).
3.4. Joint PHOSPHO1 and TNAP activity is required for metatarsal
mineralization
Next we used metatarsals from WT E15 mice, in the presence
or absence of MLS-0038949 and MLS-0263839 (Fig. 4B), to probe
the co-operativity of PHOSPHO1 and TNAP in a physiological
ex vivo model of mineralization. The inhibitors did not affect me-
tatarsal linear growth indicating a lack of toxicity at the con-
centrations used (data not shown). Mineralization of metatarsals
cultured in the presence of βGP was unaffected by the addition of
the PHOSPHO1 inhibitors whereas TNAP inhibitors reduced mi-
neralization by 73% (Po0.001). Conversely, mineralization was
almost completely inhibited by either inhibitor when P-Cho was
the substrate. Also, in the presence of both inhibitors when using
βGP as substrate, mineralization is almost completely eliminated
(Fig. 4B). These experiments were repeated 4 times and similar
results were obtained in all occasions.4. Discussion
PHOSPHO1 is now recognized to be essential for the initiation
of skeletal mineralization. Its genetic ablation in mice results in
osteoidosis and decreased BMD which are likely to explain the
observed spontaneous fractures, bowed long bones, osteomalacia
and scoliosis in early life [19,20]. PHOSPHO1 is present and active
inside chondrocyte- and osteoblast-derived MVs through its abil-
ity to scavenge Pi from MV membrane phospholipids [17]. Fur-
thermore, whilst small molecule compounds that inhibit PHOS-
PHO1 activity decreased the ability of chick chondrocyte micro-
mass cultures and isolated MVs to mineralize this was to a lesser
extent than similarly treated MVs extracted from cultured Alpl /
osteoblasts [15,30]. This is a revealing observation and suggests
that TNAP's Pi generating ability can at least, in part, compensate
for the lack of PHOSPHO1 function in driving the mineralization
process. Moreover, the complete ablation of PHOSPHO1 function
only leads to a decrease in the calciﬁcation ability of MVs and not
to a complete lack of calciﬁcation [20]. Conversely, chondrocyte-
and osteoblast-derived MVs in hypophosphatasia patients and
Alpl / mice retain the ability to initiate intra-vesicular mineral
formation and contain HA crystals and this, we speculate, is
through the actions of PHOSPHO1 [11,31]. Both scenarios are
consistent with our recent observations in mice with a double
ablation of PHOSPHO1 and TNAP function where there is complete
lack of MV and skeletal mineralization due to a complete lack of Pi
generation from intra- and extra-vesicular sources [20]. This cur-
rent biochemical study was designed to extend these observations
and examine the functional interplay of both phosphatases in the
regulation of ECM mineralization.
We ﬁrst exploited MC3T3-E1 clones 14 and 24 because of their
reported differences in TNAP expression and mineralization ability
[21]. In this original report mineralizing clone 14 did not express
Alpl but was able to induce in vivo osteogenesis whereas the
poorly-mineralizing clone 24 cells expressed Alpl but failed to
promote in vivo osteogenesis [21]. A possible explanation for the
differing mineralization abilities of the clones are the differences
in matrix gene expression between the two clones. Previous re-
ports have shown that clone 14 cells express high levels of bone
sialoprotein (BSP), osteocalcin and Runx2 compared with clone 24
cells [21]. BSP shows a temporo-spatial pattern of expression thatclosely parallels early mineral formation and is a potent nucleator
of HA crystal formation under conditions where osteopontin is
inactive or inhibitory [32]. We conﬁrmed that clone 14 cells mi-
neralize their ECM strongly despite having very low expression
levels of TNAP but we now extend these observations by showing
that these cells express high levels of PHOSPHO1 which may
provide sufﬁcient intra-vesicular Pi for mineralization to be in-
itiated. The importance of PHOSPHO1 to the mineralization pro-
cess was further underscored by poor PHOSPHO1 expression in
clone 24 cells which mineralized their ECM less well. Deletion of
PHOSPHO1 would suppress intra-vesicular generation of Pi but
would leave extra-vesicular Pi generation via TNAP activity and
inﬂux via Pi transporters unaffected [20,31]. Therefore miner-
alization in the absence of PHOSPHO1 is a slower process. This
observation is consistent with the reduced mineralization noted in
the skeletons of Phospho1/ mice [20].
Although it is recognized that the inactivation of PHOSPHO1 in
the developing chick limb or its genetic ablation in mice results in
a osteoidosis and osteomalacia [20,30] we further exploited clone
24 cells to show that Phospho1 overexpression was sufﬁcient to
promote robust matrix mineralization in this poorly mineralizing
cell line. These data provide persuasive evidence for the im-
portance of this phosphatase to the mineralization process. Inter-
estingly, when cultured in the presence of βGP or P-Cho, Phospho1
overexpression resulted in higher TNAP protein expression; an
observation consistent with our previous reports which noted that
Phospho1-/- mice exhibit reduced TNAP expression and activity
[20]. Although the mechanism(s) by which the ablation of PHOS-
PHO1 expression results in low TNAP expression is unclear, the
transgenic overexpression of TNAP does not correct the bone os-
teomalacia of Phospho1/ mice despite normalization of their
plasma PPi levels [20]. This indicates that the elevation of serum
PPi in the Phospho1 / mouse (as a result of reduced TNAP) is not
the cause of the hypomineralized phenotype. Indeed, our more
recent studies have implicated a role for PPi induced osteopontin
expression in the hypomineralization phenotype of the
Phospho1 / mouse [33].
More deﬁnitive data on the function of PHOSPHO1 and TNAP in
promoting matrix mineralization was provided by the use of
previously validated PHOSPHO1 (MLS-0263839) and TNAP (MLS-
0038949) inhibitors [22,34]. Both inhibitors when used in-
dividually reduced mineralization levels of the Phospho1 over-
expressing C24 cells to control (empty vector transduced) levels.
Only when both inhibitors were used in combination did we note
an almost complete inhibition of all mineralization. These ob-
servations suggest non-redundant actions of PHOSPHO1 and TNAP
on the mineralization process and this supports our in vivo ob-
servations where the ablation of either PHOSPHO1 or TNAP results
in a hypomineralized skeleton whereas the double ablation of both
phosphatases leads to the complete absence of skeletal miner-
alization [21]. These data suggest that both PHOSPHO1 and TNAP
are required for the formation of a fully mineralized matrix. Using
the more physiological metatarsal mineralization model, the re-
sponse to both TNAP and PHOSPHO1 inhibitors appeared to be
substrate dependent. We know that βGP is a poor substrate for
PHOSPHO1 and therefore normal metatarsal mineralization in the
presence of BGP and MLS-0263839 was as expected [17]. Un-
expectedly, in the presence of P-Cho, a substrate for both TNAP and
PHOSPHO1, mineralization was almost completely inhibited when
either TNAP or PHOSPHO1 activity was inhibited alone and it is
unclear why residual TNAP (in the presence of PHOSPHO1 in-
hibitor) or PHOSPHO1 (in the presence of TNAP inhibitor) was not
able to maintain limited mineralization. Nevertheless, in the pre-
sence of βGP, the reduction in mineralization by the TNAP inhibitor
and the almost complete elimination of mineralization by both
inhibitors is again supportive of our previous observations that
C. Huesa et al. / Biochemistry and Biophysics Reports 4 (2015) 196–201 201both phosphatases are required for full matrix mineralization.
These data highlight the important non-redundant role of PHOS-
PHO1 and TNAP in the control of ECM mineralization. It is possible
that the initiation of skeletal mineralization involves the action of
PHOSPHO1 inside MVs together with transporter mediated inﬂux
of extra-vesicular Pi, produced by TNAP activity [31]. This con-
sequence of events, whilst attractive, needs to be examined in vivo
using the judicious use of genetic mouse models.Acknowledgments
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